Ann Lab Med.  2020 Mar;40(2):99-100. 10.3343/alm.2020.40.2.99.

From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer

Affiliations
  • 1GC Genome, Yongin, Korea. changski.md@gmail.com

Abstract

No abstract available.


MeSH Terms

Breast Neoplasms*
Breast*
Genetic Testing*

Reference

1. Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat. 2019; 51:431–437.
Article
2. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, et al. Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer. 2018; 21:1–10.
Article
3. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372:2243–2257.
Article
4. Yoo J, Lee GD, Kim JH, Lee SN, Chae H, Han E, et al. Clinical validity of next-generation sequencing multi-gene panel testing for detecting pathogenic variants in patients with hereditary breast-ovarian cancer syndrome. Ann Lab Med. 2020; 40:148–154.
Article
5. US Preventive Services Task Force. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 322:652–665.
6. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020; 40:114–121.
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr